Neoantigenics is a pre-clinical stage company focused on developing oncology theranostics (therapeutic plus diagnostic) products, founded on the novel science around oocyte (egg)-associated cancer proteins ("neoantigens") discovered at the University of Virginia. These neoantigens are uniquely expressed in a wide range of urogenital tract cancers – ovarian, uterine, bladder and renal cancers – as well as certain other cancers such as aggressive stages of pancreatic cancer, many head-and-neck cancers, lung cancer, breast cancer and some leukemias.